AYA.AX Artrya ASX down 7.42% to A$3.12 16 Mar 2026: AI diagnostics outlook

AYA.AX stock fell 7.42% to A$3.12 on 16 Mar 2026 as traders reacted to weak near-term momentum in AI-enabled imaging sales. The move closed the ASX session after a day range of A$3.06–A$3.22 and volume of 138,476 shares, below the 50‑day average of A$3.67. Investors should weigh Artrya Limited’s Salix adoption and long-term AI opportunity in coronary diagnostics against current losses and negative EPS of -0.17.

Price action and technicals: AYA.AX stock

Artrya (AYA.AX) closed at A$3.12, down A$0.25 from yesterday and trading well below the 50‑day average of A$3.67 but above the 200‑day average of A$2.65. Momentum indicators show an RSI of 46.38 and MACD of -0.08 with a histogram of 0.05, signalling neutral technicals and limited trend conviction.

Business model and growth drivers

Artrya Limited (ASX: AYA) sells Salix, a cloud AI service that automates coronary CT angiography reads to flag patients at risk of heart attack. The company’s growth depends on clinical adoption, payor recognition, and international scaling into cardiology networks where AI triage can shorten reporting times and increase scan throughput.

Financials and valuation

AYA.AX shows a market cap of A$364,160,000.00 and EPS of -0.17, producing a negative PE of -18.82. Cash per share is 0.61, book value per share is 0.71, and the price‑to‑book sits at 4.50, indicating a premium on capitalised R&D and intangibles versus current revenue.

Meyka grade and forecast: AYA.AX stock

Meyka AI rates AYA.AX with a score of 63.44 out of 100 (Grade B, HOLD). This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly A$3.05 (-2.24%), quarterly A$4.36 (+39.74%), and yearly A$7.41 (+137.37%) versus the current price of A$3.12; forecasts are model‑based projections and not guarantees.

Catalysts and risks for AI diagnostics

Near-term catalysts include additional clinical validation, reimbursement wins, and vendor integrations that lift Salix volume and ARPU. Key risks are slow hospital procurement cycles, regulatory delays in new markets, and high R&D spend that keeps EPS negative.

Trading setup and strategy: AYA.AX analysis

For traders, short‑term setup favours range trading between A$2.93 (Bollinger lower) and A$3.49 (Bollinger upper). Analysts have no published consensus price target, and company ratings show mixed signals (company rating: C, recommendation Sell), so position sizing and stop discipline are essential.

Final Thoughts

Key takeaways: AYA.AX stock closed the ASX session at A$3.12 on 16 Mar 2026 after a 7.42% drop driven by weak momentum and below‑average volume. Fundamentals show continued negative EPS (-0.17) and a price‑to‑book of 4.50, reflecting investor payment for growth potential in AI diagnostics rather than current profits. Meyka AI rates AYA.AX with a score of 63.44/100 (B, HOLD) and sees a path to A$7.41 in 12 months in its model, implying +137.37% upside from today’s price; model outputs are projections, not guarantees. Investors should balance Salix adoption signals and reimbursement progress against funding needs and execution risks. We use Meyka AI as an AI‑powered market analysis platform to monitor adoption milestones and update forecasts as clinical or commercial news arrives.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.